Last week in Boston, the SHIFTBIO team had the privilege of joining the 7th CNS Drug Delivery Summit. Our CEO Prof. Gihoon Nam took the stage to address one of the most critical hurdles in the CNS industry, creating a dual-mechanism shuttle that enhances both Blood-Brain Barrier penetration and parenchymal delivery.
A key highlight was sharing how SHIFTBIO is utilizing AI developed in collaboration with Dassault Systèmes to engineer our proprietary Natural Nanoparticle platform that solves this delivery trade-off.
Throughout the summit, we engaged in in-depth discussions with various CNS experts and Big Pharma representatives regarding our BBB-penetrating drug delivery platform. We look forward to continuing these conversations and exploring impactful collaborations!
Last week in Boston, the SHIFTBIO team had the privilege of joining the 7th CNS Drug Delivery Summit. Our CEO Prof. Gihoon Nam took the stage to address one of the most critical hurdles in the CNS industry, creating a dual-mechanism shuttle that enhances both Blood-Brain Barrier penetration and parenchymal delivery.
A key highlight was sharing how SHIFTBIO is utilizing AI developed in collaboration with Dassault Systèmes to engineer our proprietary Natural Nanoparticle platform that solves this delivery trade-off.
Throughout the summit, we engaged in in-depth discussions with various CNS experts and Big Pharma representatives regarding our BBB-penetrating drug delivery platform. We look forward to continuing these conversations and exploring impactful collaborations!